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Abstract
Background: MHC class I-peptide tetramers are currently utilised to characterize CD8+ T cell
responses at single cell level. The generation and use of MHC class II tetramers to study antigen-
specific CD4+ T cells appears less straightforward. Most MHC class II tetramers are produced with
a homogeneously built-in peptide, reducing greatly their flexibility of use. We attempted the
generation of "empty" functional HLA-DR*1101 tetramers, receptive for loading with synthetic
peptides by incubation. No such reagent is in fact available for this HLA-DR allele, one of the most
frequent in the Caucasian population.
Results: We compared soluble MHC class II-immunoglobulin fusion proteins (HLA-DR*1101-Ig)
with soluble MHC class II protein fused with an optimised Bir site for enzymatic biotynilation (HLA-
DR*1101-Bir), both produced in insect cells. The molecules were multimerised by binding
fluorochrome-protein A or fluorochrome-streptavidin, respectively. We find that HLA-DR*1101-
Bir molecules are superior to the HLA-DR*1101-Ig ones both in biochemical and functional terms.
HLA-DR*1101-Bir molecules can be pulsed with at least three different promiscuous peptide
epitopes, derived from Tetanus Toxoid, influenza HA and the tumour associated antigen MAGE-3
respectively, to stain specific CD4+ T cells. Both staining temperature and activation state of CD4+
T cells are critical for the binding of peptide-pulsed HLA-DR*1101-Bir to the cognate TCR.
Conclusion: It is therefore possible to generate a soluble recombinant HLA-DR*1101 backbone
that is receptive for loading with different peptides to stain specific CD4+ T cells. As shown for
other HLA-DR alleles, we confirm that not all the strategies to produce soluble HLA-DR*1101
multimers are equivalent.
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Background
The direct ex-vivo visualization and quantification of anti-
gen-specific T cells is key to the characterisation of com-
plex immune responses. The antigen specificity of T cells
is determined by the highly specific interaction between
their TCR and the cognate MHC-peptide complex. The
low affinity and fast off-rate of this interaction, however,
precludes its exploitation to identify specific T cells [1-5].
Tetramer technology allows to circumvent this limitation,
since the overall increased avidity of the MHC multimers
compensates for the low affinity of the TCR-peptide/MHC
interaction [6,7]. MHC class I tetramers are now indeed
largely used to characterise CD8+ T cells in many basic or
clinical settings [8-13]. By contrast, the generation of func-
tional soluble peptide/MHC class II multimers, to charac-
terise CD4+  T cell responses, seems somewhat less
straightforward. Structural differences between MHC class
I and class II molecules might account for the greater dif-
ficulties to standardise the generation and production of
MHC class II tetramers. In MHC class I molecules, the α
chain alone contains the complete peptide-binding
groove and it is stable in the soluble form when associated
with the β2-microglobulin chain [14]. In contrast, both
the α and β chain of the MHC class II molecules contrib-
utes to the formation of the peptide-binding site, and
molecular "zippers" are necessary to guide the correct
inter-chain dimerisation to stabilize the soluble recom-
binant αβ heterodimers. Moreover, owing to the different
structure of the peptide-binding groove, MHC class I and
II molecules bind peptides stably and in an homogeneous
frame or unstably and in heterogeneous frames, respec-
tively [15,16]. A variety of approaches have been used to
overcome these hurdles and, in general, it appears that
there does not exist a universal way to produce soluble
MHC class II molecules. Most of the adopted strategies,
however, generate MHC-class II molecules endowed with
little or no flexibility in terms of peptide loading. For
instance, HLA-DR1 and H2-IEk have been successfully
produced in bacteria [17-19]. In analogy with the produc-
tion of soluble MHC class I molecules, their α and β
chains are separately produced in E. coli as denatured pro-
teins, which are allowed to refold correctly as αβ het-
erodimer in the presence of a single peptide. Once
refolded, however, the MHC class II heterodimer cannot
exchange the peptide any longer. Another way to produce
functional class II tetramers relies on the generation of sol-
uble MHC class II αβ heterodimers engineered with a cov-
alently linked peptide at the N-terminus of either chain,
via a flexible amino acid linker of various lengths. This
approach results in a homogeneous binding of the target
peptides to the soluble MHC class II heterodimer [20-23].
This strategy has been successfully applied to both human
and mouse MHC class II molecules produced in the
prokaryotic as well as the eukaryotic expression system.
The latter system is generally based on insect or mamma-
lian cells, which offer the advantage over bacteria of pro-
ducing proteins in native conformation and in
glycosylated form. Although the presence of a covalently
linked peptide improves the yield of functional soluble
MHC class II tetramers, it negatively impacts on their flex-
ibility of use, forcing the separate production of a soluble
MHC II molecule for each peptide of interest.
The generation of soluble recombinant MHC class II mol-
ecules without covalently linked peptide has been success-
fully used with HLA-DR*0401 and HLA-DR0*404
molecules [23-26]. This approach permits an increased
flexibility in the usage of recombinant HLA-DR mono-
mers, which are loaded with the desired synthetic pep-
tides by in vitro incubation.
Moreover, no univocal strategy to multimerise soluble
recombinant MHC class II monomers has been yet
devised. For this purpose, in fact, two main modifications
are currently introduced at the C-terminus of the MHC
class II monomer. In the first approach, the extracellular
domains of either MHC class II α or β chain are linked to
the Ig constant region. Chimeric MHC-class II-Ig mole-
cules are generally multimerised by using protein A,
which is bivalent, thus generating a tetrameric (dimer of
dimers) peptide/MHC complex [21,22,27,28]. Alterna-
tively, the extracellular domains of MHC class II α or β
chain are linked to an enzymatic biotinylation site (Bir)
[19,20,24,29]. After labelling with biotin, tetramerisation
of MHC class II-Bir monomers is accomplished by cou-
pling with fluorochrome-conjugate streptavidin
[19,20,24].
We were interested in generating HLA-DR*1101 tetramers
to characterise CD4+ T cell responses to several peptide
epitopes derived from either environmental or tumour-
associated antigens. This molecule represents one of the
most frequent HLA-DR allele in Caucasians, being
expressed in up to 20% of the population, we therefore
decided to attempt the production of HLA-DR*1101 het-
erodimers without covalently linked built-in peptide,
receptive for loading the desired peptide by incubation.
Since no information is currently available on functional
empty tetramers made of this HLA-DR allele, and given
the premises outlined above, we compared two strategies
for the production of soluble HLA-DR*1101 molecules in
insect cells: the first generating soluble chimeric HLA-
DR*1101-Ig molecules, the second HLA-DR*1101-Bir
ones. We show here that it is indeed possible to produce
functional HLA-DR*1101 tetramers, which can be loaded
with the desired peptide after the purification of the pro-
tein. For this purpose, HLA-DR*1101-Bir molecules
resulted superior to the HLA-DR*1101-Ig chimeric con-
structs.BMC Immunology 2005, 6:24 http://www.biomedcentral.com/1471-2172/6/24
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Results
Production and biochemical characterisation of soluble 
HLA-DR*1101 molecules
To produce HLA-DR*1101-Ig and HLA-DR*1101-Bir
molecules, the cDNAs coding the extracellular domains of
the HLA-DR α and the HLA-DR*1101 β chain were fused
in frame at the 5' end with the sequence encoding for the
Drosophila leader peptide Bip, and at the 3' end with the
Construction of soluble recombinant HLA-DR*1101-Ig and HLA-DR*1101-Bir molecules Figure 1
Construction of soluble recombinant HLA-DR*1101-Ig and HLA-DR*1101-Bir molecules. Structure and homoge-
neity of purified soluble HLA-DR*1101 recombinant molecules. (a) Schematic representation of HLA-DR*1101-Ig and HLA-
DR*1101-Bir constructs. The extracellular region of HLA-DR*1101β is fused with the Basic Zipper (BZ) and His tag. The HLA-
DRα chain is fused with the Acid Zipper (AZ) and the human (h)IgG1 constant region or the biotynilation site BirA, respec-
tively. All constructs are cloned into the pMT/V5/His Drosophila expression vector, in frame with the Drosophila leader 
sequence Bip, under the control of a metallotioneine promoter, inducible by CuSO4 addition. The HLA-DR*1101-Ig molecule is 
secreted into the supernatant of Drosophila cells as dimer of HLA-DR*1101α/β heterodimers, because of a disulphide bond 
between two hIgG domains. (b) SDS-PAGE of HLA-DR*1101-Ig molecules secreted into the supernatant of S2 cells (sup) after 
CuSO4 induction, and after purification by protein A affinity chromatography (Prot A). Gels were run either in reducing (+βm) 
or non-reducing (-βm) conditions. Indicated are the bands corresponding to the migration of the HLA-DRα-hIg homodimers, 
HLA-DRα-hIg monomers and HLA-DR*1101β-His tag proteins. (c) Western blotting analysis of HLA-DR*1101-Ig molecules, 
separated on SDS-PAGE as shown in (b). The blotted filter was probed at the same time with the anti-His tag and anti-hIg 
probes, as indicated in figure. Empty circle and asterisk indicate the migration of the HLA-DRα-hIg and HLA-DR*1101β-His 
tag, respectively. (d) SDS-PAGE analysis of the HLA-DR*1101-Bir molecule contained into the supernatant (sup) of S2 cells 
after CuSO4 induction, and after purification by immunoaffinity chromatography with L243 mAb (L243).BMC Immunology 2005, 6:24 http://www.biomedcentral.com/1471-2172/6/24
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Soluble recombinant HLA-DR*1101-Ig and HLA-DR*1101-Bir molecules display different biochemical properties Figure 2
Soluble recombinant HLA-DR*1101-Ig and HLA-DR*1101-Bir molecules display different biochemical proper-
ties. Characterization of the native structure and stability of both soluble recombinant HLA-DR*1101 molecules. (a) Immuno-
precipitation of HLA-DR*1101-Ig and HLA-DR*1101-Bir molecule with 30 µl of L243-sepharose beads from 1 ml of S2 cells 
culture supernatant after CuSO4 induction. The lanes contain the following material: 1. sup, 30 µl of culture supernatant 
before immunoprecipitation; 2. bound, the immunoprecipitated soluble recombinant HLA-DR*1101; and 3. not bound, 30 µl of 
culture supernatant after immunoprecipitation. Proteins were separated on SDS-page, transferred to filter and revealed with 
anti his-tag antibody. (b) Densitometric analysis of the protein bands displayed in panel (a), showing the elative efficiency of 
immunoprecipitation of the two soluble recombinant HLA-DR*1101 proteins with L243-Sepharose beads, as an indirect indica-
tor of the percentage of correctly folded molecule. (c) Size exclusion chromatography of HLA-DR*1101-Ig molecules, after 
purification of ProtA affinity chromatography. The elution profile of the molecule from a Superdex 200 gel filtration column is 
shown. Inset shows the dot-blot analysis performed on the protein contained in the indicated elution peaks. Spotted proteins 
are probed with either anti-His tag antibody, to verify the presence of the HLA-DR*1101 molecule, or L243 mAb (Anti-HLA-
DR) to verify the correct conformation of the molecule. (d) Elution profile from Superdex 200 gel filtration column and dot-
blot analysis on eluted peaks of HLA-DR11-Bir molecules, performed as described in (c). (e) Calibration profile of the Super-
dex 200 gel filtration column.BMC Immunology 2005, 6:24 http://www.biomedcentral.com/1471-2172/6/24
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acidic (AZ) and basic (BZ) leucin zipper sequences,
respectively (Figure 1a). A sequence coding a hexahisti-
dine tag (His tag) was subsequently added at the 3' end of
the HLA-DR*1101 β chain cDNA (Figure 1a).
To generate a chimeric HLA-DR*1101-Ig molecules, the
DR α chain was linked at the 3' end with a cDNA encoding
for the hinge and Fc fragment of human IgG1 (Figure 1a).
To allow targeted biotin-labelling, the HLA-DRα-AZ chain
was fused at the 3' end to a sequence coding a peptide rec-
ognized by the BirA enzyme (Figure 1a).
Each construct was stably transfected into S2 Drosophila
melanogaster cells, that were initially grown in selective
medium as bulk culture. To stabilise and optimise the
production of both recombinant soluble HLA-DR*1101
molecules, bulk cultures of transfected S2 cells were
cloned by limiting dilution, and clones producing highest
quantity of soluble molecules were selected and
expanded.
The HLA-DR*1101-Ig recombinant molecule was secreted
in the culture supernatant as dimers of αβ heterodimers,
owing to the presence of an inter-chain disulfide bond
between two Ig hinge regions, and was purified using an
affinity chromatography with protein A-sepharose (Figure
1b). The formation of the disulfide bond between two
chimeric HLA-DRα-Ig molecules was confirmed by SDS-
PAGE of the purified molecules under reducing and non-
reducing condition, followed by western blot analysis
using anti-His tag and anti-Ig antisera (Figure 1c).
The HLA-DR*1101-Bir recombinant molecule was
secreted as αβ heterodimer by S2 cells and purified by
immunoaffinity chromatography with the human HLA-
DRα chain-specific mAb L243 (Figure 1d). Noteworthy,
the L243 mAb binds a conformational epitope on HLA-
DRα which depends on the correct folding of the αβ het-
erodimer [30,31].
The immunoprecipitation of HLA-DR*1101-Ig and HLA-
DR*1101-Bir molecules with the mAb L243 shows that
only a little fraction of HLA-DR*1101-Ig molecule can be
bound by the mAb, and most of the protein remains in
the culture supernatant, suggesting that the secreted HLA-
DR*1101-Ig molecules have lost the native conformation
recognised by L243 (Figure 2a). A second immunoprecip-
itation of HLA-DR*1101-Ig molecules from the same
supernatant with fresh L243-conjugated beads did not
precipitated additional soluble molecule, ruling out that
the little protein precipitated was the result of insufficient
amounts of mAb-conjugated beads (data not shown). By
contrast, as shown in Figure 2a, almost all the HLA-
DR*1101-Bir molecule contained in the culture superna-
tant was immuno-precipitated by the L243-conjugated
beads, suggesting that this type of soluble recombinant
protein exhibit a correct conformation for mAb binding.
Based on the densitometric analysis of the immunopre-
cipitated molecules, we assumed that only 30% of the
HLA-DR*1101-Ig molecule present in the supernatant
displayed a correct conformation, in contrast with nearly
100% of correct conformation displayed by the HLA-
DR*1101-Bir molecule (Figure 2b). Considering that we
have selected transfected S2 cell clones that secreted simi-
lar amounts of either soluble recombinant HLA-DR*1101
molecule (not shown), we would need to produce three
times more supernatant of HLA-DR*1101-Ig than HLA-
DR*1101-Bir to purify the same amount of correctly
folded molecule.
To further verify the biochemical properties and stability
of the two types HLA-DR*1101 molecules, we performed
analytical size-exclusion chromatography on the purified
proteins. Figure 2c–d shows the elution profile of HLA-
DR*1101-Ig and of HLA-DR*1101-Bir molecules, respec-
tively. The HLA-DR*1101-Ig molecule was eluted in two
peaks at elution volume of 7,5 ml, corresponding to the
void volume of the column, and 10,6 ml, corresponding
to >900 and 500 Kda respectively. Since the expected
molecular weight for the HLA-DR*1101-Ig molecule is
about 300 KDa, this result suggested a high propensity of
the molecule towards aggregation. Moreover, a dot blot
analysis could detect the DR1101 protein in the two main
elution peaks only when an anti His-tag antibody, but not
when the L243 antibody, was utilised. These results fur-
ther indicated that the HLA-DR*1101-Ig molecule was
unstable and tended to progressively aggregate after puri-
fication. On the contrary, the elution profile of HLA-
DR*1101-Bir (Figure 2d) showed a single symmetric peak
at an elution volume of 13,6 ml, corresponding to the
expected molecular weight of 80 KDa of the HLA-
DR*1101-Bir αβ heterodimer. In this case, the molecule
could be detected in a dot-blot with both the anti His-tag
mAb and the L243 antibody, indicating that the molecule
was correctly folded.
Altogether these data indicate that the HLA-DR*1101-Bir
exhibited superior biochemical quality to HLA-DR*1101-
Ig molecule both in terms of tertiary/quaternary structure
and stability.
Peptide loading of soluble HLA-DR11 molecules
The relative disadvantage in the production of HLA-
DR*1101-Ig molecules could be compensated by possible
peculiar physical properties displayed by this molecule in
comparison with HLA-DR*1101-Bir molecules. We spec-
ulated in fact that, once pulsed with peptide and tetramer-
ised, the presence of the flexible Ig hinge region in the
HLA-DR*1101-Ig construct could represent an advantage
and facilitate the binding of cognate TCRs, in comparisonBMC Immunology 2005, 6:24 http://www.biomedcentral.com/1471-2172/6/24
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HLA-DR*1101-Ig and HLA-DR*1101-Bir molecules can be loaded with synthetic peptides Figure 3
HLA-DR*1101-Ig and HLA-DR*1101-Bir molecules can be loaded with synthetic peptides. Purified soluble HLA-
DR*1101-Ig and HLA-DR*1101-Bir molecules were loaded with equal amount of p2 peptide. Stability of the peptide-loaded 
HLA-DR*1101 αβ heterodimers was determined by running complexes in reducing condition on SDS gels without boiling, or 
by testing their capacity to elicit IFN-γ production in specific CD4+ T cell clones. (a) SDS-resistance assay of HLA-DR*1101-Bir 
molecules. Indicated are the protein bands corresponding to the migration of either the HLA-DR*1101-Bir αβ heterodimer, or 
the single HLA-DRα-Bir or HLA-DR*1101β chains. Lane nil: unloaded HLA-DR*1101-Bir molecules. Lane p2: p2-loaded HLA-
DR*1101-Bir molecules. (b) SDS-resistance assay of HLA-DR*1101-Ig molecules. Indicated are the protein bands correspond-
ing to the migration of either the HLA-DR*1101-Ig αβ heterodimer, or the single HLA-DRα-Ig or HLA-DR*1101β chains. Lane 
nil and p2 are the same as per HLA-DR*1101-bir. (c) IFN-γ production by the p2-specific CD4+ T cell clone (TCC) 162 in 
response to p2-loaded HLA-DR*1101-Bir or HLA-DR*1101-Ig molecules, attached to plastic. The response of the MAGE-3 
p39-specific CD4+ TCC 2C3.35 is shown as control. T cells were cultured in the presence of the indicated peptide-pulsed 
HLA-DR*1101 recombinant molecules, in the presence of a costimulatory dose of PMA. As control, T cells were cultured in 
the presence only of sub-optimal doses of PMA (PMA), or activated by plastic-bound anti-CD3 mAb (Anti-CD3). The release 
of IFN-γ in the culture supernatant was determined by ELISA 48 h later.BMC Immunology 2005, 6:24 http://www.biomedcentral.com/1471-2172/6/24
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HLA-DR*1101-Bir, but not HLA-DR*1101-Ig, stain specific CD4+ T cells, and display a temperature-dependence Figure 4
HLA-DR*1101-Bir, but not HLA-DR*1101-Ig, stain specific CD4+ T cells, and display a temperature-depend-
ence. CD4+ TCC specific for p2, endowed with different affinity of recognition, and an irrelevant CD4+ TCC were stained 
with p2-loaded HLA-DR*1101-Bir tetramers at different temperature. (a) The relative affinity for the p2-HLA-DR*1101 dis-
played by the two TCC clones 162 and 51 is determined in an IFN-γ-releasing assay following production in response to differ-
ent doses of p2 peptide. 104 T cells are incubated with 5 × 104 HLA-DR*1101 LCL cells and the indicated doses of p2 peptide. 
After 48 hours, the concentration of IFN-γ in the culture supernatant is measured by ELISA. Indicated are the concentration of 
p2 peptide required to elicit half-maximum release of IFN-γ in the two TCC. (b) Staining of TCC162, TCC51 and the irrelevant 
TCC with either p2-loaded HLA-DR*1101-Ig or p2-loaded HLA-DR*1101-Bir tetramers. Staining is performed for 2 hours at 
the indicated temperatures with 10 µg of tetramer per sample. The tetramer staining on CD3+CD4+ gated cells is shown. The 
amount of surface TCR, obtained by staining with anti-CD3 mAb, expressed by the TCC in the different conditions is shown 
by the mean fluorescent intensity (CD3 mfi).BMC Immunology 2005, 6:24 http://www.biomedcentral.com/1471-2172/6/24
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with the more rigid HLA-DR*1101-Bir molecules. For this
reason, we investigated the functional properties of both
HLA-DR*1101-Ig and HLA-DR*1101-Bir molecules. The
purified soluble HLA-DR*1101 molecules were loaded
with the Tetanus Toxoid-derived peptide TT830–845 (p2), a
very well characterized promiscuous peptide binding with
high affinity to different HLA-DR alleles [32]. Both puri-
fied HLA-DR*1101-Ig and HLA-DR*1101-Bir molecules
were incubated for 72 hours at 37°C in a mild acidic
buffer (pH 5) in the presence of a 50 fold molar excess of
p2 peptide. The efficacy of peptide loading was then eval-
uated by a SDS-resistance assay [33]. The high affinity
binding of a peptide to the HLA-DR groove stabilize in
fact the association between the HLA-DR α and β chains,
making in some cases the αβ heterodimer resistant to the
denaturing action of SDS at r.t. [33]. As shown in Figure
3a, the "empty" (nil) HLA-DR*1101-Bir molecules were
denatured upon incubation in SDS-containing buffer at
r.t., and the DRα and β chains migrated as separated
chains in both boiled (B) and not boiled (NB) samples.
On the contrary, the binding of p2 substantially stabilised
the HLA-DR αβ heterodimer, leading to the appearance of
an 80 KDa band in the gel, corresponding to the peptide-
MHC complex. Unlike HLA-DR*1101-Bir molecules, the
incubation in SDS at r.t. did not induce dissociation of
HLA-DR*1101-Ig α and β chains even when the p2 pep-
tide was not added (Figure 3b). These results indicated
that the HLA-DR*1101-Ig molecule displayed a stronger
HLA-DR*1101-Bir tetramer staining correlates with the activation state of the target CD4+ T cells Figure 5
HLA-DR*1101-Bir tetramer staining correlates with the activation state of the target CD4+ T cells. The p2-spe-
cific CD4+ TCC 162 was stained with p2-loaded HLA-DR*1101-Bir tetramers at different time after in vitro restimulation with 
p2 and APCs. The histograms in the upper row display the amount of surface TCR (mfi) expressed by the T cells at the time of 
tetramer staining, as determined by anti-CD3 staining. The histograms in the lower row show the staining with the p2-loaded 
HLA-DR*1101-Bir tetramers (mfi) performed at the indicated time after restimulation.BMC Immunology 2005, 6:24 http://www.biomedcentral.com/1471-2172/6/24
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Peptide-loaded HLADR1101-Bir tetramers stain polyclonal T cells specific for p2 and HA Figure 6
Peptide-loaded HLADR1101-Bir tetramers stain polyclonal T cells specific for p2 and HA. In vitro expanded T cells 
were stained with HLA-DR*1101-Bir tetramers loaded with either p2 or HA peptides. (a) Staining of PBMCs from a HLA-
DR*1101 healthy donor after one round of in vitro stimulation with 5 µM of p2-peptide and 40 u/ml of IL-2. (b) Intracellular 
production of IFN-γ by T cells contained in the p2-enriched PBMC. T cells were stimulated for 6 hours with p2 in the presence 
of HLA-DR*1101+ LCL cells at 37°C. Brefeldin A was added after the first hour of stimulation. The cells were then fixed, per-
meabilised and stained with anti-IFN-γ mAb. Cells unstimulated (nil) and stimulated policlonally with PMA-Ionomycin (PMA/
ionomycin) are shown as controls. Numbers in quadrants indicate the percentage of T cells stained with anti-IFN-γ mAb (c) 
Staining of PBMCs from HLA-DR*1101 healthy donor with HA-loaded HLA-DR*1101-Bir tetramers. T cells were after three 
rounds of in vitro stimulation with 1 µg/ml of HA peptide and 40 u/ml of IL-2. The staining is performed at the indicated days 
after the third stimulation. Numbers in quadrants indicate the percentage of T cells stained by HLA-DR tetramers. (d) Intracel-
lular production of IFN-γ by CD4+ T cells contained in the HA-specific T cell line at day 8 from the third in vitro stimulation. 
Activation and staining of CD4+ T cells was performed as described in (b).BMC Immunology 2005, 6:24 http://www.biomedcentral.com/1471-2172/6/24
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interaction between the α and β chains, as compared to
HLA-DR*1101-Bir molecules, precluding the quantifica-
tion of peptide loading by this method.
To characterise further the loading of both soluble recom-
binant HLA-DR*1101 molecules with the exogenous pep-
tides, we relied on an indirect functional assay, in which
p2-loaded HLA-DR*1101 molecules were utilised in vitro
to activate p2-specific CD4+ T cells. Since the assay was
performed in the absence of antigen presenting cells, a
sub-optimal dose of phorbol myristate acetate (PMA) was
added as costimulatory signal for T cells. As shown in Fig-
ure 3c, both TT830–845-loaded HLA-DR*1101-Ig and HLA-
DR*1101-Bir molecules were able to induce IFN-γ pro-
duction by p2-specific CD4+ T cells, but not by CD4+ T
cells specific for an irrelevant peptide or restricted for
another HLA-DR allele. These results indicated that both
HLA-DR*1101-Ig and HLA-DR*1101-Bir molecules
could be loaded in vitro with a peptide of interest.
Staining of specific CD4+ T cells with peptide-loaded HLA-
DR*1101 tetramers
We finally compared the staining capacity of both soluble
HLA-DR*1101 molecules, loaded with different CD4
peptide epitopes. We selected for the staining experiment
two p2-specific CD4+ T cell clones displaying low and
high affinity for the peptide respectively, as shown in Fig-
ure 4a. HLA-DR*1101-Ig or HLA-DR*1101-Bir were
loaded with p2 peptide, multimerized and used for the
staining at 4°C or 37°C, according to previous data sug-
gesting a significant temperature effect on the interaction
between the TCR and the peptide-pulsed MHC-class II
tetramers [25,34].
As shown in Figure 4b, HLA-DR*1101-Ig tetramers did
never stain either p2-specific T cell clones at any tempera-
ture. By contrast, HLA-DR*1101-Bir tetramers stained
both low and high affinity p2-specific T cells, although the
low affinity T cells clone could only be stained at 37°C,
while the high affinity one could be stained at both tem-
perature, though with a much higher fluorescence inten-
sity at 37°C. Collectively these results indicated that HLA-
DR*1101-Bir tetramers stain peptide-specific CD4+  T
cells, and required an optimal temperature of staining of
37°C. By contrast, HLA-DR*1101-Ig could not stain pep-
tide-specific T cells, despite their capacity to be loaded
with peptides.
Staining with HLA-DR*1101-Bir tetramers depends on the 
activation state of CD4+ T cells
In an independent series of experiments, we noticed that
the staining level of CD4+ T cells by peptide-pulsed HLA-
DR*1101-Bir molecules was consistently higher when T
cells had been recently restimulated with either cognate
peptide or polyclonal stimuli in the presence of PBMCs as
APCs. This observation prompted a more systematic
investigation of the phenomenon. This is in fact a relevant
issue when considering the use of HLA-DR*1101 tetram-
ers for ex vivo staining, since primary CD4+ T cells might
display a whole range of different activation states, which
in turn could affect the "detectability" of the whole pep-
tide-specific T cell repertoire by the HLA-DR*1101 tetram-
ers. We therefore compared the capacity of HLA-
DR*1101-Bir tetramer to stain the high affinity p2-specific
CD4+ T cell clone 162 at different time points from restim-
ulation. As shown in Figure 5, the 162 T cell clone could
be stained progressively less by p2-HLADR1101 tetramers
moving from day 5 to day 14 post-restimulation, even
though the mean fluorescence value of the cell-surface
CD3-TCR complex was not substantially modified in the
three conditions. This finding confirmed that the activa-
tion state of the target CD4+ T cells influences the binding
of HLA-DR*1101-Bir tetramers to the TCR.
HLA-DR*1101-Bir tetramers stain polyclonal CD4+ T cells 
specific for p2 or Influenza Hemagglutinin HA peptides
We next verified the capacity of HLA-DR*1101-Bir tetram-
ers to detect polyclonal antigen-specific CD4+ T cells. Two
different helper epitopes from proteins expressed by envi-
ronmental pathogens were selected: TT-p2 and Influenza
Hemagglutinin HA306–318 (HA) [35], another well charac-
terised and commonly utilised promiscuous CD4 epitope.
PBMCs from healthy donors were stained with p2-pulsed
or HA-pulsed HLA-DR*1101-Bir tetramers either ex vivo
or at different time points after in vitro stimulation with
the corresponding peptide. In line with published data
[24,26,36], p2- or HA-specific CD4+  T cells could be
hardly detected ex vivo by HLA-DR*1101-Bir tetramers
pulsed with either peptides (data not shown), with fre-
quencies of tetramer positive cells in the range of those
obtained with peptide-unloaded (empty) HLA-DR*1101
tetramer (0,05–0,1%). After 4 days of stimulation in vitro
with the specific peptide, however, a sizeable fraction of
CD4+ T cells could be clearly detected with either peptide-
pulsed-HLA-DR*1101-Bir tetramer (Figure 6a,c), with a
background staining with peptide-unloaded tetramers in
the order of 0,05–0,07% in the two T cell cultures (data
not shown). The percentage of CD4+ T cells stained with
the tetramers paralleled fairly accurately the percentage of
cells that were able to produced IFN-γ upon in vitro stim-
ulation with the corresponding peptide at the same time
point (Figure 6b,d). Again, the percentage of CD4+ T cells
stainable with peptide-HLA-DR*1101-Bir tetramers
declined with time following the in vitro stimulation with
the peptide, confirming at the polyclonal level what
observed with T cell clones specific for p2, although the
decline of staining of HA-specific CD4+ T cells was more
rapid than that of p2-specific ones.BMC Immunology 2005, 6:24 http://www.biomedcentral.com/1471-2172/6/24
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HLA-DR*1101-Bir tetramers stain CD4+ T cells specific for 
the MAGE-3 tumour antigen derived M3191–205 (p39) 
peptide
We were also interested in determining whether HLA-
DR*1101-Bir tetramers could stain CD4+ T cells specific
for the naturally processed, promiscuous p39 peptide
derived from the MAGE-3 TAA [37]. As shown in Figure 7,
the p39-specific CD4+  T cell clone 2C3.35 could be
stained with p39-pulsed HLA-DR*1101-Bir tetramers.
The affinity of this CD4+ T cell clone for the p39 peptide,
as shown in a dose response experiment of IFN-γ produc-
tion (Figure 7b), was even lower to that of the low affinity
T cell clone 51 for p2 peptide, explaining the low mfi
value obtained by staining the 2C3.35 T cell clone with
p39-HLA-DR*1101-Bir tetramers. Thus, HLA-DR*1101-
Bir tetramers could be pulsed also with a naturally proc-
essed promiscuous tumour-derived peptide, and might
prove useful in characterising naturally arising or thera-
peutically induced CD4+  T cells responses in HLA-
DR*1101 patients with tumours expressing MAGE-3.
Discussion
We have shown the generation of a versatile HLA-
DR*1101 tetramer. A single soluble recombinant protein
backbone can bind at least three different promiscuous
peptide epitopes, derived from environmental pathogens
or tumour associated antigens, by a simple incubation
step. This feature will greatly facilitate the use of this rea-
gent for the study of CD4+ T cells responses specific for
disparate antigens. The usefulness of this approach is evi-
dent also from the studies performed with HLA-DR*0401
and HLA-DR*0404 tetramers [23-26], in which the same
protein backbone was loaded with either viral or self-
derived peptide. The only HLA-DR*1101 tetramers
described so far are produced in E coli with a covalently
linked HCV-derived peptide [38] and, although func-
tional, are limited in their use to the single peptide specif-
icity. Therefore, the production of versatile HLA-DR*1101
tetramers is extremely valuable considering the frequency
of expression of this allele in the Caucasian population.
It is interesting to note that the same extracellular portion
of the HLA-DR allele behaves differently in terms of stabil-
ity when engineered with different C-terminal moieties.
The presence of an Ig constant domain at the C-terminus
seems in fact to destabilise the "empty" HLA-DR*1101
soluble recombinant molecule significantly more than
the presence of the Bir sequence. The most straightforward
explanation for this phenomenon holds that the extended
intermolecular interactions introduced by the pairing of
two Ig Fcs may disturb the native conformation of the chi-
meric HLA molecules. In fact our results show that the
addition of a short Bir sequence at the C-terminus does
not impact on the overall molecular architecture of this
human HLA-DR allele. Evidence for a conformational
alteration in the HLA-DR*1101-Ig molecule stems from
the immuno-precipitation experiments with the anti-
HLA-DRα chain-specific monoclonal antibody L243,
which recognizes a conformational epitope that is present
only when the HLA-DRα and β chain are correctly paired
[30,31]. L243 immunoprecipitates very inefficiently HLA-
DR*1101-Ig molecules, whereas it efficiently binds HLA-
DR*1101-Bir, suggesting differences in the structures of
the two proteins or a masked epitope in the former. Sev-
eral mouse MHC class II alleles have nevertheless been
successfully produced as chimeric MHC-Ig fusion pro-
teins, with or without a linked peptide, and it is possible
that HLA-DR alleles other than DR1101 might be pro-
duced in this chimeric form.
It is clear from our study that the affinity of the TCR
expressed by the CD4+ T cells for the cognate peptide-
HLA-DR*1101 complex will dictate the success of detec-
HLA-DR*1101-Bir tetramers stain CD4+ T cells specific for  the MAGE-3 tumour antigen derived p39 epitope Figure 7
HLA-DR*1101-Bir tetramers stain CD4+ T cells spe-
cific for the MAGE-3 tumour antigen derived p39 
epitope. Ability of p39-loaded HLA-DR*1101-Bir tetramers 
to stain a specific CD4+ TCC. (a) Clone M3 2C3.35 was 
assayed for IFN-γ production to different doses of p39 pep-
tide. 104 T cells are incubated for 48 hours with 5 × 104 HLA-
DR*1101+ LCL cells and the indicated doses of p39 peptide. 
IFN-γ in the supernatant is measured by ELISA. (b) Staining of 
a MAGE-3-specific T cell clone. The cells are stained at day 
19 from re-stimulation with 10 µg of either CLIP-loaded or 
p39-loaded HLA-DR*1101-Bir tetramers for 2 hours at 
37°C.BMC Immunology 2005, 6:24 http://www.biomedcentral.com/1471-2172/6/24
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tion of specific primary lymphocyte population by the flu-
orescent tetramer. Moreover, we document that the
activation state of the target CD4+ T cells affects the bind-
ing of peptide-HLA-DR tetramers to the cognate TCR, sug-
gesting that biochemical pathways linked to CD4+ T cell
activation modify the avidity of the TCR for the HLA-DR
tetramer. The fact that the binding of the TCR by the cog-
nate peptide-HLA-DR*1101 tetramers requires an active
metabolism and intact membrane trafficking is suggested
further by the 37°C temperature requirement for optimal
CD4+  T cell staining. Collectively, these observations
might help to explain why the detection ex-vivo of primary
CD4+ T cells by MHC class II tetramers seems more diffi-
cult than the detection of specific CD8+ T cells by MHC
class I tetramers. Further study are needed to determine
whether modifying rationally the structure of the helper
peptide epitope to increase its affinity for the MHC class II
allele and/or the cognate TCR, and manipulating the T cell
activation pathways to increase the avidity of the TCR for
HLA-DR tetramers, my lead to improved ex-vivo detection
of specific CD4+ T cells.
Conclusion
In conclusion, we report here the successful engineering
of stable empty HLA-DR*1101-Bir tetramers. These mole-
cules are novel powerful reagents for the study of CD4+ T
cell responses towards diverse peptide antigens. Our com-
parative study on the production of two different "empty"
HLA-DR*1101 constructs, together with the evidences
present in the literature, suggests that every MHC class II
isotype, and even allele, might display distinct biochemi-
cal characteristics, requiring the empiric definition of the
optimal strategy for the production as functional soluble
recombinant molecules.
Methods
Construction of soluble recombinant HLA-DR*1101-Ig and 
HLA-DR*1101-Bir molecules for insect cells expression
All the DR α and β constructs were cloned in the pMT/Bip/
V5-His vector (Invitrogen, Groningen, the Nederlands) in
frame with the Drosophila BiP secretion signal, under the
control of the Drosophila metallothionein promoter.
The extracellular region of the HLA-DRα chain, deprived
of the leader sequence, was cloned by RT-PCR using the
following primers: oligo-1-Up DRα (BglII)
5'GGGAGATCTATCAAAGAAGAACATGTGATCATCCAG3
', oligo-2-Dw DRα (BamHI)
5'GGATCCTCCACCTCCGTTCTCTGTAGTCTCTGGG3'.
The PCR product was cloned into the PCR2.1 vector (Inv-
itrogen) and sequenced.
To generate the HLA-DRα-Bir chain, a cassette containing
the sequence for the Acidic Leucine Zipper-Bir A target
peptide was generated by fusion PCR with the following
primers, as illustrated in Figure 1:
Oligo-3-Up AZ (BamHI)
5'GGAGGATCCACTACAGCTCCATCAGCTCAG3', Oligo-
4-Dw AZ (Bir)
5'ACCACCACCGTCCCCACCCTGAGCCAGTTC3', Oligo-
5-Up Bir (AZ)
5'GGTGGGAGCGGTGGTGGTCTGAACGATATTTTTG3'
and Oligo-6-Dw Bir (NotI)
5'CTAGCGGCCGCTATTCATGCCATTCGAT3'. The PCR
product was cloned into the PCR2.1 vector and
sequenced, then subcloned in frame with the HLA-DRα
fragment separated by a five-aminoacid linker (GGGGS).
The resulting sequence encoding the HLA-DRα-AZ-Bir
fusion protein was excised with BglII and NotI restriction
enzymes, and cloned into the Drosophila melanogaster
expression vector pMT/Bip/V5/His.
To generate the HLA-DRα-Ig chain, a cassette containing
the sequence for the Acidic Leucine Zipper-hIgG1 con-
stant region was generated by fusion PCR as illustrated in
Figure 1, using the following primers:
oligo-3-upAZ(BamHI) described above, oligo-9-Dw AZ
(Ig) AGATTTGGGCTCAGATGCTGCCTGAGCCAGTTC,
oligo-10-Up Ig (AZ) GCAGCATCTGACGCCCAAARCTT-
GTGACAAAACTCAC and oligo-11-Dw IgG1 (NotI)
5'TGGCGGCCGCCGCACTCATTTACCCGGAGA. The
PCR product was cloned into the PCR2.1 vector,
sequenced and then subcloned in frame with the HLA-
DR*1101α chain fragment. The resulting sequence encod-
ing for the HLA-DR*1101α-AZ-IgG1 fusion protein was
excised with BglII and NotI, and cloned in the Drosophila
melanogaster expression vector pMT/Bip/V5/His.
The HLA-DR*1101β chain, shared by both type of soluble
recombinant HLA-DR*1101 molecules, was generated as
follows. The extracellular region of the HLA-DR*1101β,
chain deprived of its leader sequence, was cloned by RT-
PCR using the following primers:
oligo-7-Up DRβ (BglII)
5'GGGAGATCTGGGGACACCAGACCACGTTTC3', oligo-
8-Dw DRβ (BamHI)
5'GTGGATCCTCCACCTCCCTTGCTCTGTGCAGATTC3'.
The PCR product was cloned into the PCR2.1 vector and
sequenced. The HLA-DR*1101β cDNA was subcloned in
frame with a Basic Leucine Zipper-His tag cassette derived
from the pCO268 plasmid spaced by a five-aminoacid
linker (GGGGS) [21]. The resulting coding sequence was
then excised with BglII and SalI restriction digestion, and
cloned into the Drosophila melanogaster expression vec-
tor pMT/Bip/V5/His, digested with BglII and XhoI.BMC Immunology 2005, 6:24 http://www.biomedcentral.com/1471-2172/6/24
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Expression of HLA-DR*1101 in Drosophila cells
S2 cells were grown in SFX medium (Hy-clone, South
Logan, UT, USA) supplemented with 10% heat inacti-
vated foetal calf serum (Euroclone, Milano, Italy), 50 u/
ml penicillin, 25 µg/ml streptomycin, 25 µg/ml Kanamy-
cin (Gibco) and 1 µg/ml Amphotericin B (Gibco, Paisley,
Scotland, UK) at 27°C to a density of 2–4 × 106 cells/ml.
The α- and β-chain expressing vectors (15 µg each) were
co-transfected with 0,5 µg of the selection plasmid pCo-
HYGRO using a calcium phosphate transfection kit (Inv-
itrogen). Three days after the transfection, selection
medium containing 300 µg/ml of Hygromicin B (Roche,
Indianapolis, IN, USA) was added to cells. Transfected
cells were cultured in SFX medium supplemented with
2% of foetal calf serum and 300 µg/ml of Hygromicin B.
Cells were kept in the exponential growth phase (7–20 ×
106 cells/ml) and the protein production was induced by
the addition of 1 mM of CuSO4 when the cells were at a
density of 107/ml. Protein production was monitored by
dot blot analysis with either mouse anti-human HLA-DR
α monoclonal antibody L243 (ATCC, Manassas, VA, USA)
or rabbit anti-His tag polyclonal antibody His-probe
(Santa Cruz, Santa Cruz, CA, USA), followed by an HRP-
labelled goat anti mouse or anti rabbit antibody (South-
ern Biothecnology, Birmingham, AL, USA). The assay was
developed with ECL (Amersham, Uppsala, Sweden). To
improve the production of recombinant proteins, trans-
fected cells were cloned by limiting dilution. S2 cells
expressing the desired HLA-DR*1101 molecule were
diluted to 2.5 cell/ml in a suspension of irradiated (8000
rad) S2 wild type cells at the concentration of 3 × 105 cells/
ml in medium+Hygromicin B, and plated in flat bot-
tomed 96 w plates. The best producer clones were selected
by dot blot analysis on the culture supernatant as
described above, upon induction with 1 mM of CuSO4 of
the same number of cells, and used for routine protein
production.
Purification of soluble HLA-DR*1101 molecules
Both HLA-DR*1101-Ig and HLA-DR*1101-Bir molecules
were purified from the S2 cells supernatant by immunoaf-
finity chromatography using ProtA-Sepharose (Amer-
sham Bioscience) and HLA-DRα-specific L243 mAb-
Sepharose, respectively. The HLA-DR*1101-Ig molecules
were stored at -80°C at a concentration of 1 mg/ml in PBS
buffer. HLA-DR*1101-Bir molecules were dialyzed
against 10 mM Tris buffer, pH 8.0, and concentrated up to
3 mg/ml on Vivaspin2 concentrator (Vivascience, Hanno-
ver, Germany). The protein was biotinylated using the
BirA enzyme according to the manufacturer's instructions
(Avidity, Denver, CO, USA), then was diluted to 1 mg/ml
and stored at -80°C. The formation of molecular aggre-
gates was assessed by size exclusion chromatography on a
Superdex 200 HR 10/30 column using a ÅKTA FPLC chro-
matography system (Amersham Bioscience). The calibra-
tion of the Superdex 200 column was performed with the
Gel Filtration Calibration Kit high molecular weights
(Amersham Bioscience), following the manufacturer indi-
cations. Partition coefficients were calculated using the
relation Kd = (Ve-Vo)/(Vc-Vo), where Ve, Vc and Vo are
the elution, column and void volumes, respectively.
Peptide loading into soluble HLA-DR*1101 molecules
Both HLA-DR*1101-Ig and HLA-DR*1101-Bir were
loaded with synthetic peptides by incubation at 37°C for
72 hours with 50 fold molar excess of either Tetanus Tox-
oid peptide residues 829–844 (p2), Hemagglutinin pep-
tide residues 306–318 (HA) or MAGE-3 tumour
associated antigen peptide residues 191–205 (p39) in 10
mM Tris, 50 mM Glycine pH 5.0 with 0.2% of n-octyl-β-
D-glucopyranoside (Sigma-Aldrich, St. Louis, MO, USA).
Tetramerization of soluble HLA-DR*1101 molecules and 
staining of specific T cells
Tetramerization of HLA-DR*1101-Ig and HLA-DR*1101-
Bir were achieved by adding FITC-labelled protein A
(Molecular Probes, Leiden, The Netherlands) at 5:1 molar
ratio, or PE-labelled streptavidin (Molecular Probes) at
5:1 molar ratio, respectively. Tetramer staining was per-
formed for 2 hours at 37°C in complete medium. The
cells are then washed twice, transferred on ice and stained
for the other surface markers. Immediately before the
analysis TOPRO-3 (Molecular Probes) is added following
the manufacturer's instructions to exclude dead cells. The
analysis is performed on CD3+CD4+ viable cells.
Generation of specific CD4+ T cell lines and clones
20 million of freshly purified PBMCs from a HLA-
DR*1101/1104 healthy donor were cultured for 7 days in
RPMI 1640 (Gibco) supplemented with 10% of human
serum, 2 mM Glutamax I (Gibco), 100 u/ml penicillin
and 50 µg/ml streptomycin (Gibco), in the presence of the
specific peptide at a concentration ranging from 1 to 10
µg/ml. After seven days, blasts were separated from small
T cells on a 30–70% discontinuous Percoll gradient [39],
and put in culture in complete medium with 10–20 u/ml
of human recombinant IL-2 (Roche). Peptide specific T
cells were kept in culture by weekly re-stimulation with
the same amount of peptide and irradiated (4000 rad)
autologous PBMCs as antigen presenting cells. Peptide-
specific T cell clones were generated by limiting dilution
of Percoll-purified T cell blasts blasts as follows. Blasts
were diluted at 25 cells/ml in a suspension containing 0.5
× 106 cells/ml of a mixture of two different allogeneic
PBMCs supplemented with 1 µg/ml of PHA-L (Roche)
and 200 u/ml of human recombinant IL-2 (Roche). The
cloning mix is dispensed in 25 µl in flat-bottomed Teras-
aki plates and incubated at 37°C for 10–20 days. Growing
cells are then tested for the recognition of peptide pulsed
HLA matched EBV cell lines.BMC Immunology 2005, 6:24 http://www.biomedcentral.com/1471-2172/6/24
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T cells functional assays
To test IFN-γ production, 104 T cells were plated in U bot-
tom 96 well plates in RPMI 1640 supplemented with 10%
of human serum, 2 mM Glutamax I, 100 u/ml penicillin,
50 µg/ml streptomycin, together with 5 × 104 irradiated
(6000 rad) HLA-DR*1101 LCL cells as antigen presenting
cells, and the specific peptide at the concentrations
detailed in the figure legends. IFN-γ production in the
supernatant was measured by ELISA after 48 hours of
incubation (IFN-γ detection kit-Endogen).
For the intracellular analysis of IFN-γ production, T cells
were stimulated for 6 hours with HLA-DR*1101 LCL of at
1:5 ratio in three conditions: i. without peptide; ii. with 5
µg/ml of peptide; and iii. with 50 ng/ml of PMA (Sigma)
plus 500 ng/ml of Ionomycin (Sigma). After the first hour
of stimulation, Brefeldin A was added at the final concen-
tration of 10 µg/ml. At the end of the stimulation, the cells
were harvested, fixed with PFA1%, permeabilized with
0,5% saponin and stained for intracellular cytokine
expression.
For the T cell activation with peptide-loaded soluble
recombinant HLA-DR molecules, 1 µg of peptide loaded
HLA-DR*1101-Ig or HLA-DR11-Bir molecules in 50 µl of
PBS were incubated in U bottomed 96 well plates for 3
hours at 37°C. After washing, 2 × 104 specific T cells were
added to the wells and incubated for 48 hours at 37°C in
the presence of 1 ng/ml of PMA. Cells incubated either
with PMA alone or in the presence of 1 µg of plate coated
TR66 anti-CD3 mAb are used as negative and positive
control, respectively. IFN-γ production in the supernatant
is measured by ELISA (Endogen, Woburn, MA, USA) after
48 hours of culture.
Antibodies and flow cytometry
The following antibodies have been used: FITC- and APC-
labelled mouse anti human CD3 (Becton Dickinson, San
Jose, CA, USA), Quantum Red-conjugated mouse anti-
human CD4 (SIGMA), PE-labelled rat anti-human IFN-γ
(Becton Dickinson). Data were collected using a Becton
Dickinson FACScalibur flow cytometer and analysed
using the Cell Quest software (Becton Dickinson)
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